SIALYLATION OF ANTI-HISTONE ANTIBODIES IN BLOOD SERUM OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
SIALYLATION OF ANTI-HISTONE ANTIBODIES IN BLOOD SERUM OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
DOI: http://dx.doi.org/10.30970/sbi.0603.239
Abstract
Anti-histone autoantibodies belong to main marker antibodies used in the diagnostics of systemic lupus erythematosus (SLE) patients. During autoimmune diseases, especially in SLE, prevalent process of inflammation is caused by high titers of auto-antibodies. It is known that the level of IgG sialylation affect their anti-inflammatory properties. The aim of the experiments was to investigate the level of sialylation of anti-histone IgG-antibodies from blood serum of patients with SLE. Investigation was carried out by two methodological approaches. In the first case, the antibodies were purified from blood serum by affine chromatography on histone-Sepharose and protein G-Sepharose followed by Western blot detection of sialic acid residues in the carbohydrate chaines of IgG molecules using sialospecific previously biotinylated Sambucus nigra lectin (SNA). In the second case, IgG-antibodies were isolated from blood serum by affine chromatography on protein G-Sepharose, this fraction was separated on sialylated and not sialylated IgG by SNA-Sepharose chromatography followed by checking their affinity to histones by ELISA. In this manuscript, it is shown that the level of sialylation of anti-histone IgG is lower than in control preparation of antibodies. Our data showed that anti-histone autoantibodies are devoid of sialic acid residues at the ends of the carbohydrate chains of Fc-fragments promote their inflammatory properties in patients with SLE.
Note: ELISA – enzyme linked immunosorbent assay, Ab – antibodies, auto-Ab – auto-antibodies.
Keywords
Full Text:
PDF (Українська)References
1. Dimitrov J.D., Bayry J., Siberil S., Kaveri S.V. Sialylated therapeutic IgG: a sweet remedy for inflammatory diseases? Nephrol. Dial. Transplant, 2007; 22(5): 1301-4. | |
| |
2. Lim P.L., Zouali M. Pathogenic autoantibodies: emerging insights into tissue injury. Immunol. Lett, 2006; 103(1): 17-26. | |
| |
3. Scanlan C.N., Burton D.R., Dwek R.A. Making autoantibodies safe. Proc. Natl. Acad. Sci USA, 2008; 105(11): 4081-2. | |
| |
4. Anthony R.M., Ravetch J.V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol, 2010; 30(Suppl 1): S9-14. | |
| |
5. Albert H., Collin M., Dudziak D. et al. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc. Natl. Acad. Sci. USA, 2008; 105(39): 15005-9. | |
| |
6. Kaneko Y., Nimmerjahn F., Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 2006; 313(5787): 670-3. | |
| |
7. Butler M., Quelhas D., Critchley A.J. et al. Detailed glycan analysis of serum glycoproteins of patients with congenital disorders of glycosylation indicates the specific defective glycan processing step and provides an insight into pathogenesis. Glycobiology, 2003; 13(9): 601-22. | |
| |
8. Nimmerjahn F., Anthony R.M., Ravetch J.V. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc. Natl. Acad. Sci. USA, 2007; 104(20): 8433-7. | |
| |
9. Anthony R.M., Wermeling F., Ravetch J.V. Novel roles for the IgG Fc glycan. Ann NY Acad. Sci, 2012; 1253: 170-80. | |
| |
10. Bach J.F., Koutouzov S., Van Endert P.M. Are there unique autoantigens triggering autoimmune diseases? Immunol. Rev, 1998; 164: 139-55. | |
| |
11. Isenberg D.A. Systemic lupus erythematosus: immunopathogenesis and the card game analogy. J. Rheumatol. Suppl, 1997; 48: 62-6. | |
| |
12. Tan E.M. Antinuclear antibodies: diagnostic markers and clues to the basis of systemic autoimmunity. Pediatr. Infect. Dis. J, 1988; 7(5 Suppl): S3-9. | |
| |
13. Kubota T. [Advances in systemic lupus erythematosus]. Nihon Rinsho, 1999; 57(2): 329-32. | |
| |
14. Nezlin R., Alarcon-Segovia D., Shoenfeld Y. Immunochemical determination of DNA in immune complexes present in the circulation of patients with systemic lupus erythematosus. J. Autoimmun, 1998; 11(5): 489-93. | |
| |
15. Nimmerjahn F., Ravetch J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med, 2007; 204(1): 11-5. | |
| |
16. Magorivska I.B., Bilyy R.O., Havrylyuk A.M. et al. Anti-histone H1 IgGs from blood serum of systemic lupus erythematosus patients are capable of hydrolyzing histone H1 and myelin basic protein. J. Mol. Recognit, 2010; 23(5): 495-502. | |
| |
17. Anthony R.M., Nimmerjahn F., Ashline D.J. et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science, 2008; 320(5874): 373-6. | |
| |
18. Tan E.M. Pathophysiology of antinuclear antibodies in systemic lupus erythematosus and related diseases. Adv. Dent. Res, 1996; 10(1): 44-6. | |
| |
19. Stadlmann J., Weber A., Pabst M. et al. A close look at human IgG sialylation and subclass distribution after lectin fractionation. Proteomics, 2009; 9(17): 4143-53. | |
| |
20 Bilyy R., Tomin A., Tolstyak Ya. et al. Cell Surface Glycans at SLE - Changes during cells death, utilization for disease detection and molecular mechanism underlying their modification. In Autoimmune Disorders - Pathogenetic Aspects / ed.: Mavragany C.P. InTech, Rijeka, Croatia, 2011. P. 89-110. | |
| |
21. Shkandina T., Herrmann M., Bilyy R. Sweet kiss of dying cell: Sialidase activity on apoptotic cell is able to act toward its neighbors. Autoimmunity, 2012 (PMID: 22928616). | |
| |
22. Bilyy R., Tomin A., Mahorivska I. et al. Antibody-mediated sialidase activity in blood serum of patients with multiple myeloma. J. Mol. Recognit, 2011; 24: 576-584. | |
Refbacks
- There are currently no refbacks.
Copyright (c) 2012 Studia biologica
This work is licensed under a Creative Commons Attribution 4.0 International License.